Search results

Skip to results

Type

Status

Last updated

Showing 16 to 30 of 62 results for ipilimumab

  1. Lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma (TA858)

    Evidence-based recommendations on lenvatinib (Kisplyx) with pembrolizumab (Keytruda) for untreated advanced renal cell carcinoma in adults.

    Technology appraisal guidance
    Published
    11 January 2023
    View recommendations

    Sections for TA858

  2. Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency (TA914)

    Evidence-based recommendations on pembrolizumab (Keytruda) for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency in adults.

    Technology appraisal guidance
    Published
    20 September 2023
    View recommendations

    Sections for TA914

  3. Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma (TA766)

    Evidence-based recommendations on pembrolizumab (Keytruda) for adjuvant treatment of completely resected stage 3 melanoma in adults.

    Technology appraisal guidance
    Published
    2 February 2022
    View recommendations

    Sections for TA766

  4. Tebentafusp for treating advanced uveal melanoma (TA1027)

    Evidence-based recommendations on tebentafusp (Kimmtrak) for treating uveal melanoma in adults.

    Technology appraisal guidance
    Published
    9 January 2025

    Sections for TA1027

  5. Renal cell carcinoma Pathways Pilot [ID6186]

    In development [GID-TA11186] Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Melanoma (metastatic) - talimogene laherparepvec [ID508]

    In development [GID-TAG509] Expected publication date: 28 September 2016

    Technology appraisal guidance
    In development

  7. Further research into whether concomitant dacarbazine enhances the clinical effectiveness of ipilimumab would be encouraged because it could provide information for future treatment strategies, as would more data on the relative effectiveness of ipilimumab when given as a first-line or second-line treatment.

    whether concomitant dacarbazine enhances the clinical effectiveness of ipilimumab would be encouraged because it could provide...

    Research recommendation
    Published
    9 June 2015

  8. Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma (TA837)

    Evidence-based recommendations on pembrolizumab (Keytruda) for the adjuvant treatment of resected stage 2B and 2C melanoma in people 12 years and over.

    Technology appraisal guidance
    Published
    26 October 2022
    View recommendations

    Sections for TA837

  9. Avelumab with axitinib for untreated advanced renal cell carcinoma (MA review of TA645) [ID6294]

    In development [GID-TA11587] Expected publication date: 25 June 2025

    Technology appraisal guidance
    In development

  10. NICE considered that more research is needed to establish the treatment sequence for vemurafenib and ipilimumab in patients who have BRAF V600 mutation-positive melanoma.

    research is needed to establish the treatment sequence for vemurafenib and ipilimumab in patients who have BRAF V600 mutation-positive...

    Research recommendation
    Published
    9 June 2015

  11. Nivolumab with ipilimumab for untreated advanced hepatocellular carcinoma [ID6239]

    Awaiting development [GID-TA11116] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma (TA321)

    Evidence-based recommendations on dabrafenib (Tafinlar) for treating unresectable or metastatic melanoma in adults with a BRAF V600 mutation.

    Technology appraisal guidance
    Published
    22 October 2014
    View recommendations

    Sections for TA321

  13. Nivolumab with ipilimumab for adjuvant treatment of localised renal cell carcinoma [TSID9659]

    Awaiting development [GID-TA11111] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation‑positive malignant melanoma (TA269)

    Evidence-based recommendations on vemurafenib (Zelboraf) for treating advanced BRAF V600-positive malignant melanoma in adults.

    Technology appraisal guidance
    Last updated
    1 January 2015
    View recommendations

    Sections for TA269

  15. Pembrolizumab with axitinib for untreated advanced renal cell carcinoma (TA650)

    Evidence-based recommendations on pembrolizumab (Keytruda) with axitinib (Inlyta) for untreated advanced renal cell carcinoma in adults.

    Technology appraisal guidance
    Published
    30 September 2020
    View recommendations

    Sections for TA650